tetano
Editor, Senior Moderator
Heliyon
. 2022 Jan;8(1):e08835.
doi: 10.1016/j.heliyon.2022.e08835. Epub 2022 Jan 26.
Remdesivir for pregnancy: A systematic review of antiviral therapy for COVID-19
David Setyo Budi[SUP] 1 [/SUP], Nando Reza Pratama[SUP] 1 [/SUP], Ifan Ali Wafa[SUP] 1 [/SUP], Manesha Putra[SUP] 2 [/SUP], Manggala Pasca Wardhana[SUP] 3 [/SUP], Citrawati Dyah Kencono Wungu[SUP] 4 5 [/SUP]
Affiliations
Abstract
Objective: The use of remdesivir for pregnant patients with coronavirus disease 2019 (COVID-19) showed conflicting results in prior studies. We aimed to systematically review its efficacy and safety for this population from the existing literature.
Methods: On July 26, 2021, registries (ClinicalTrials.gov) and databases (MEDLINE, ScienceDirect, Cochrane Library, JSTOR, DOAJ, and medRxiv) were systematically searched for research articles investigating remdesivir use in pregnant people with COVID-19. Clinical outcome, hospitalization duration, laboratory outcome, mortality, and adverse events were investigated.
Results: We obtained 13 observation studies with 113 pregnant people. In these studies, remdesivir improved the clinical condition of pregnant patients with COVID-19, especially those who had a better clinical status at baseline and received earlier remdesivir treatment. Most fetuses were delivered via cesarean section, primarily because of emergency causes. No vertical transmissions were noted. The most reported adverse event was transaminitis, in which 10-day remdesivir treatment yielded more incidence than the 5-day treatment.
Conclusions: In pregnancy, the use of Remdesivir in combination with other COVID-19 treatments is inconclusive but its use should be followed with careful monitoring of adverse reactions and transaminase enzyme levels. Further studies are required to confirm its finding.
Keywords: Antiviral therapy; COVID-19; Pregnancy; Remdesivir; SARS-CoV-2.
. 2022 Jan;8(1):e08835.
doi: 10.1016/j.heliyon.2022.e08835. Epub 2022 Jan 26.
Remdesivir for pregnancy: A systematic review of antiviral therapy for COVID-19
David Setyo Budi[SUP] 1 [/SUP], Nando Reza Pratama[SUP] 1 [/SUP], Ifan Ali Wafa[SUP] 1 [/SUP], Manesha Putra[SUP] 2 [/SUP], Manggala Pasca Wardhana[SUP] 3 [/SUP], Citrawati Dyah Kencono Wungu[SUP] 4 5 [/SUP]
Affiliations
- PMID: 35128114
- PMCID: PMC8802673
- DOI: 10.1016/j.heliyon.2022.e08835
Abstract
Objective: The use of remdesivir for pregnant patients with coronavirus disease 2019 (COVID-19) showed conflicting results in prior studies. We aimed to systematically review its efficacy and safety for this population from the existing literature.
Methods: On July 26, 2021, registries (ClinicalTrials.gov) and databases (MEDLINE, ScienceDirect, Cochrane Library, JSTOR, DOAJ, and medRxiv) were systematically searched for research articles investigating remdesivir use in pregnant people with COVID-19. Clinical outcome, hospitalization duration, laboratory outcome, mortality, and adverse events were investigated.
Results: We obtained 13 observation studies with 113 pregnant people. In these studies, remdesivir improved the clinical condition of pregnant patients with COVID-19, especially those who had a better clinical status at baseline and received earlier remdesivir treatment. Most fetuses were delivered via cesarean section, primarily because of emergency causes. No vertical transmissions were noted. The most reported adverse event was transaminitis, in which 10-day remdesivir treatment yielded more incidence than the 5-day treatment.
Conclusions: In pregnancy, the use of Remdesivir in combination with other COVID-19 treatments is inconclusive but its use should be followed with careful monitoring of adverse reactions and transaminase enzyme levels. Further studies are required to confirm its finding.
Keywords: Antiviral therapy; COVID-19; Pregnancy; Remdesivir; SARS-CoV-2.